Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Botox® (onabotulinumtoxinA) – Expanded indication
October 18, 2019 - The FDA approved Allergan’s Botox (onabotulinumtoxinA), for the treatment of lower limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy.
